Who makes 0.1% and 0.4% perineural ropivicaine?

0.1% and 0.4% perineural ropivicaine is developed by University of California, San Diego.

What development phase is 0.1% and 0.4% perineural ropivicaine in?

0.1% and 0.4% perineural ropivicaine is FDA-approved (marketed).

Last reviewed 2026-05-15 · How we verify

0.1% and 0.4% perineural ropivicaine

University of California, San Diego · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	0.1% and 0.4% perineural ropivicaine
Sponsor	University of California, San Diego
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Optimizing Local Anesthetic Concentration for Continuous Lumbar Plexus Nerve Blocks (PHASE4)
Optimizing Local Anesthetic Concentration for Continuous Femoral Nerve Blocks (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

0.1% and 0.4% perineural ropivicaine CI brief — competitive landscape report
0.1% and 0.4% perineural ropivicaine updates RSS · CI watch RSS
University of California, San Diego portfolio CI